- Home
- INCY vs DECK Comparison
INCY vs DECK Comparison
Compare INCY & DECK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- DECK
- Stock Information
- Founded
- INCY 1991
- DECK 1973
- Country
- INCY United States
- DECK United States
- Employees
- INCY N/A
- DECK N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- DECK Shoe Manufacturing
- Sector
- INCY Health Care
- DECK Consumer Discretionary
- Exchange
- INCY Nasdaq
- DECK Nasdaq
- Market Cap
- INCY 13.0B
- DECK 15.2B
- IPO Year
- INCY 1993
- DECK 1993
- Fundamental
- Price
- INCY $70.20
- DECK $116.92
- Analyst Decision
- INCY Hold
- DECK Buy
- Analyst Count
- INCY 20
- DECK 22
- Target Price
- INCY $72.75
- DECK $140.00
- AVG Volume (30 Days)
- INCY 1.5M
- DECK 4.3M
- Earning Date
- INCY 07-29-2025
- DECK 07-24-2025
- Dividend Yield
- INCY N/A
- DECK N/A
- EPS Growth
- INCY N/A
- DECK 24.81
- EPS
- INCY 0.10
- DECK 6.53
- Revenue
- INCY $4,413,226,000.00
- DECK $5,124,803,000.00
- Revenue This Year
- INCY $13.48
- DECK $10.34
- Revenue Next Year
- INCY $10.37
- DECK $7.78
- P/E Ratio
- INCY $723.63
- DECK $17.91
- Revenue Growth
- INCY 17.13
- DECK 15.49
- 52 Week Low
- INCY $53.56
- DECK $93.72
- 52 Week High
- INCY $83.95
- DECK $223.98
- Technical
- Relative Strength Index (RSI)
- INCY 55.91
- DECK 66.42
- Support Level
- INCY $67.17
- DECK $103.87
- Resistance Level
- INCY $71.29
- DECK $108.85
- Average True Range (ATR)
- INCY 1.51
- DECK 3.54
- MACD
- INCY 0.06
- DECK 1.56
- Stochastic Oscillator
- INCY 74.23
- DECK 69.88
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About DECK Deckers Outdoor Corporation
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2025, Ugg and Hoka accounted for 51% and 45% of total sales, respectively. The firm also markets niche brands Teva and Ahnu. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and about 180 company-operated stores. It generated 64% of its fiscal 2025 sales in the United States.